RETRACTED: Systematic Review and Meta-Analysis of Clinical Efficacy and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections
International Journal of Molecular Sciences · 04.09.2024 · 25 (17) · 9574
DOI: 10.3390/ijms25179574 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.09.2024. Verfasst von Alexandra Bucataru und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. Hauptthemen laut MEDLINE: Carbapenem-Resistant Enterobacteriaceae, Meropenem, Anti-Bacterial Agents, Enterobacteriaceae Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine and Pharmacy of Craiova.
Abstract (Originalsprache)
Antimicrobial resistance is increasingly concerning, causing millions of deaths and a high cost burden. Given that carbapenemase-producing Enterobacterales are particularly concerning due to their ability to develop structural modifications and produce antibiotic-degrading enzymes, leading to high resistance levels, we sought to summarize the available data on the efficacy and safety regarding the combination of meropenem-vaborbactam (MV) versus the best available therapy (BAT). Articles related to our objective were searched in the PubMed and Scopus databases inception to July 2024. To assess the quality of the studies, we used the Cochrane risk-of-bias tool, RoB2. The outcomes were pooled as a risk ratio (RR) and a 95% confidence interval (95%CI). A total of four published studies were involved: one retrospective cohort study and three phase 3 trials, including 432 patients treated with MV and 426 patients treated with BAT (mono/combination therapy with polymyxins, carbapenems, aminoglycosides, colistin, and tigecycline; or ceftazidime-avibactam; or piperacillin-tazobactam). No significant difference in the clinical response rate was observed between MV and the comparators at the TOC (RR = 1.29, 95%CI [0.92, 1.80], p = 0.14) and EOT (RR = 1.66, 95%CI [0.58, 4.76], p = 0.34) visits. MV was associated with a similar microbiological response as the comparators at TOC (RR = 1.63, 95%CI [0.85, 3.11], p = 0.14) and EOT assessment (RR = 1.16, 95%CI [0.88, 1.54], p = 0.14). In the pooled analysis of the four studies, 28-day all-cause mortality was lower for MV than the control groups (RR = 0.47, 95%CI [0.24, 0.92], p = 0.03). MV was associated with a similar risk of adverse events (AEs) as comparators (RR = 0.79, 95%CI [0.53, 1.17], p = 0.23). Additionally, MV was associated with fewer renal-related AEs than the comparators (RR = 0.32, 95%CI [0.15, 0.66], p = 0.002). MV was associated with a similar risk of treatment discontinuation due to AEs (RR = 0.76, 95%CI [0.38, 1.49], p = 0.42) or drug-related AEs (RR = 0.56, 95%CI [0.28, 1.10], p = 0.09) as the comparators. In conclusion, MV presents a promising therapeutic option for treating CRE infections, demonstrating similar clinical and microbiological responses as other comparators, with potential advantages in mortality outcomes and renal-related AEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Infectious Disease Department, Victor Babes University Hospital Craiova, 200515 Craiova, Romania.
- Pharmacoeconomics Department, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Ophthalmology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Bacteriology-Virology-Parasitology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
ORCID-Profile: Alexandra Bucataru, Adina Turcu-Stiolica, Daniela Calina, Ovidiu Mircea Zlatian, Alice Elena Ghenea
Förderung
- University of Medicine and Pharmacy of Craiova
Zitieren
APA
Bucataru, A., Turcu-Stiolica, A., Calina, D., Balasoiu, A. T., Zlatian, O. M., Osman, A., Balasoiu, M., & Ghenea, A. E. (2024). RETRACTED: Systematic Review and Meta-Analysis of Clinical Efficacy and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. International Journal of Molecular Sciences, 25(17), 9574. https://doi.org/10.3390/ijms25179574
Vancouver
Bucataru A, Turcu-Stiolica A, Calina D, Balasoiu AT, Zlatian OM, Osman A, et al. RETRACTED: Systematic Review and Meta-Analysis of Clinical Efficacy and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. International Journal of Molecular Sciences. 2024;25(17):9574. doi:10.3390/ijms25179574
BibTeX
@article{Bucataru2024,
author = {Bucataru, Alexandra and Turcu-Stiolica, Adina and Calina, Daniela and Balasoiu, Andrei Theodor and Zlatian, Ovidiu Mircea and Osman, Andrei and Balasoiu, Maria and Ghenea, Alice Elena},
title = {RETRACTED: Systematic Review and Meta-Analysis of Clinical Efficacy and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {17},
pages = {9574},
doi = {10.3390/ijms25179574}
}
EUVIMED